Streetbeat News

Regulatory

SPY

President Biden commented on the April Consumer Price Index (CPI) report, stating that prices are still too high. This indicates ongoing inflation concerns.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 1:39 pm

PULM

Pulmatrix, Inc. (NASDAQ:PULM) announced the publication of clinical results for its orally inhaled DHE (PUR3100) for acute migraine in the peer-reviewed journal Headache: The Journal of Head and Face Pain. The study showed that PUR3100 has rapid systemic pharmacokinetics and improved safety and tolerability compared to intravenously administered DHE. The FDA has accepted an IND application for a Phase 2 study, making PUR3100 Phase 2-ready.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 1:31 pm

CRLBF

Cresco Labs Inc. reported its Q1 2024 financial results, highlighting a 10x increase in operating cash flow year-over-year. The company maintained flat revenue at $184 million, improved its adjusted gross profit by 7%, and reduced adjusted SG&A expenses by 24%. Cresco also retained its No.1 market share in Illinois, Pennsylvania, and Massachusetts. CEO Charles Bachtell expressed optimism about potential federal rescheduling of cannabis.

Portfolio Pulse from Jelena Martinovic

May 15, 2024 | 1:25 pm

IKT

Inhibikase Therapeutics (NASDAQ:IKT) has requested the withdrawal of its S-1 Registration Statement filed with the SEC. No securities have been sold in connection with this offering.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 1:13 pm

AMC

GME

AMC Entertainment Holdings Inc (NYSE:AMC) shares are trading lower on Wednesday after announcing agreements to issue stock in exchange for notes and completing an equity offering. The stock had previously rallied alongside GameStop Corp (NYSE:GME) due to renewed interest from Keith Gill, known as 'Roaring Kitty'.

Portfolio Pulse from Adam Eckert

May 15, 2024 | 1:05 pm

ACXP

Acurx Pharmaceuticals has reported a successful FDA end-of-Phase 2 meeting and is ready to advance ibezapolstat into Phase 3 clinical trials for treating C. difficile Infection. The company has also received SME designation from the EMA, which provides fee incentives and support for EU Marketing Authorization.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 1:02 pm

CTHR

Charles & Colvard has announced a 1-for-10 reverse stock split effective May 17, 2024, to comply with Nasdaq's $1.00 minimum bid price requirement. Split-adjusted trading will begin on the same day.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:56 pm

BNR

Trading for BNR was halted and then resumed at 8:55:00 AM ET. The halt was due to pending news, and trading resumed after the news was released.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:55 pm

HMNF

Trading halt status was updated at 8:55:00 AM ET, indicating a resumption of quotations. The news and resumption times are provided.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:55 pm

MBRX

Moleculin Biotech has commenced a Phase 2 clinical trial of its STAT3 inhibitor, WP1066, for glioblastoma. The trial, funded by the NIH, is being conducted at Northwestern University and combines WP1066 with radiation, showing promising results in animal models.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:40 pm